Avista Capital Partners has acquired Terrats Medical, a Spain-based provider of dental prosthetics, from private equity firm Miura Partners, for an undisclosed price.
As part of the deal, the founders of Terrats Medical have made further investments in the company and will continue to lead it.
Miura Partners has also made additional investments in the business with plans to support the Spanish firm in its next stage of growth.
Terrats Medical produces and sells a range of implants, abutments, and associated items under the DESS Dental Smart Solutions brand. Its abutments are said to be compatible with popular implant systems sold by dental original equipment manufacturers (OEMs).
Customers of the company include dental implant OEMs as well as dental offices, labs, and distributors, who buy its products on a private-label basis.
The Spanish dental prosthetics company earns more than 95% of its revenue through exports with sales to more than 50 countries.
Avista Capital Partners partner Sriram Venkataraman said: “Terrats has earned its leading reputation in the marketplace by producing high quality products that are broadly compatible and accessible.
“The Company is well-positioned to accelerate growth as favourable sector trends continue, particularly growing demand in the dental prosthetics market.”
Miura Partners made its first investment in Terrats Medical in 2020 which helped the latter boost its growth and enhance operations.
Following the investment, the Spanish firm could expand its digitisation strategy, launch its implantology business, improve direct sales under the DESS brand, and acquire distributors Humanus Dental in Sweden and Geryon in the US.
Terrats Medical CEO Roger Terrats said: “We are thrilled to begin working with Avista Capital Partners, which has a proven track record in the dental sector and the US markets. Their support will help us build upon the growth initiatives launched in 2008 and continued in 2020 with the entry of Miura Partners.
“Our vision for the next stage will be very consistent and focused on global growth, with a top-notch product suite and strong sales network that will be fortified in the coming years. Additionally, we look forward to continuing to invest in our production and our team.”
